This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Acadia (ACAD) Down 13.9% Since Last Earnings Report?
by Zacks Equity Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Acadia (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Acadia (ACAD) posts wider-than-expected loss for the first quarter of 2022 while revenues miss estimates.
Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of -42.86% and 6.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Surges 23.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Zymeworks Inc. (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia (ACAD) Stock Down as Pain Candidate Misses Study Goal
by Zacks Equity Research
Acadia's (ACAD) phase II study, evaluating ACP-044 for treating acute pain following bunionectomy surgery, misses the primary endpoint. Stock down.
Why Is Acadia (ACAD) Up 1% Since Last Earnings Report?
by Zacks Equity Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Acadia (ACAD) Stock Up on FDA's Action Date for Nuplazid sNDA
by Zacks Equity Research
Acadia (ACAD) gets an action date of Aug 4, 2022, from the FDA for its resubmitted sNDA for pimavanserin to treat hallucinations and delusions associated with Alzheimer's disease psychosis.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Acadia (ACAD) Q4 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Acadia (ACAD) posts a wider-than-expected loss for the fourth quarter of 2021. Shares fall during the after-hours trading.
Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of -12.50% and 3.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Acadia Pharmaceuticals (ACAD) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Much a $1000 Investment in Acadia Pharmaceuticals Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
4 Drug, Biotech Stocks Set to Beat Q4 Earnings Estimates
by Ekta Bagri
Let us take a look at some drug/biotech stocks like VIR, MRNA, JAZZ and ACAD that are poised to beat on fourth-quarter earnings.
Phillips (PHG) Blends 3D Mapping With Zenition, Aids Prospects
by Zacks Equity Research
Phillips (PHG) integrates AI and 3D mapping capabilities it its Mobile C-Arm System, Zenition, enhancing its diagnostic imaging portfolio.
Acadia (ACAD) Up More Than 20% in Past 3 Months: Here's Why
by Zacks Equity Research
Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, has seen strong uptake so far. Its label expansion studies also hold promise.
Acadia (ACAD) Partners With Stoke for CNS Disorder Therapies
by Zacks Equity Research
Acadia (ACAD) signs a collaboration agreement with Stoke Therapeutics to develop/commercialize RNA-based medicines for addressing genetic neurodevelopmental diseases.
ACADIA (ACAD) Up on Resubmission Plan for Nuplazid sNDA to FDA
by Zacks Equity Research
ACADIA (ACAD) to resubmit sNDA for Nuplazid (pimavanserin) to the FDA for treating hallucinations and delusions associated with dementia focused on Alzheimer's disease psychosis. Shares rise.
Biotech Stock Roundup: ACAD Up on Study Results, BHVN's Pipeline Update & More
by Ekta Bagri
Acadia's (ACAD) study results and other pipeline updates have been the biotech sector's few key highlights during the past week.
ACADIA's (ACAD) Rett Syndrome Candidate Meets Goal in Study
by Zacks Equity Research
ACADIA's (ACAD) phase III study, evaluating the efficacy and safety of trofinetide in patients with Rett syndrome, meets co-primary endpoints. Shares rise.
ACADIA's (ACAD) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
ACADIA Pharmaceuticals (ACAD) posts narrower-than-expected loss for the third quarter of 2021. Revenues also beat estimates. Resultantly, its shares rise in after-hours trading.
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of 66.67% and 3.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Should Schwab U.S. MidCap ETF (SCHM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHM
Humana (HUM) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Humana's (HUM) third-quarter earnings are expected to have gained from higher revenues and a solid contribution from its Retail and Healthcare Services segments.